Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In recent years, there has been a tremendous advance in our understanding of the cellular functions of individual RecQ helicases. This Review discusses how these proteins might suppress genomic rearrangements, and therefore function as 'caretaker' tumour suppressors.
The PI3K–Akt pathway is vital to the growth and survival of cancer cells and consequently inhibitors targeting this pathway are entering clinical trials. What is the therapeutic potential of such drugs and what might the challenges and limitations be?
The human tumour suppressor LKB1 directly phosphorylates and activates AMPK, a central metabolic sensor. AMPK is a key therapeutic target in patients with diabetes, and the connection between AMPK and several tumour suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants investigation in patients with cancer.
Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) signalling pathways are involved in a vast array of cellular events and are often altered in human cancers. This Review discusses how studies in mouse models have contributed to our understanding of the functions of these pathways in different cancers, and the implications for therapeutic approaches.
A major challenge exists in assessing the risk of developing cancer from exposures to low-dose radiation — which are encountered during diagnostic scans, for example. What factors influence low-dose cancer risk and what might this mean for current protection measures?
The pharmacological activity of tamoxifen is dependent on metabolic conversion by the enzyme cytochrome P450 2D6 (CYP2D6). This Review discusses the existing data that relateCYP2D6 genotypes to tamoxifen response. Can the analysis of CYP2D6genotype be used to optimize breast cancer therapy?